Rituximab biosimilars for lymphoma in Europe

References

• European Medicines Agency. MabThera summary of product characteristics (SmPC) 2016. Available from: https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf
   Google Scholar
• Grillo-Lopez AJ, White CA, Dallaire BK, et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol. 2000;1(1):1–9. PubMed PMID: 11467356.
   PubMedGoogle Scholar
• Feugier P. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin’s lymphomas. Future Oncol. 2015;11(9):1327–1342. PubMed PMID: 25952779
   PubMed Web of Science ®Google Scholar
• Pierpont TM, Limper CB, Richards KL. Past, present, and future of rituximab-the world’s first oncology monoclonal antibody therapy. Front Oncol. 2018;8:163. PubMed PMID: 29915719; PubMed Central PMCID: PMC5994406
   PubMed Web of Science ®Google Scholar
• Salles G, Barrett M, Foa R, et al. Rituximab in B-cell hematologic malignancies: A review of 20 years of clinical experience. Adv Ther. 2017 Oct;34(10):2232–2273. PubMed PMID: 28983798; PubMed Central PMCID: PMC5656728.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Ghielmini M, Rule S, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016 Sep;27(suppl 5):v83–v90. PubMed PMID: 27664263.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment Report: Rixathon 2017 [cited 2019 Jul 19]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003903/WC500232462.pdf
   Google Scholar
• European Medicines Agency. Assessment Report: Truxima 2016 [cited 2019 Jul 19]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/truxima-epar-public-assessment-report_en.pdf
   Google Scholar
• Leung LK, Mok K, Liu C, et al. What do oncologists need to know about biosimilar products? Chin J Cancer. 2016;35(1):91. PubMed PMID: 27733189; PubMed Central PMCID: PMC5062853
   PubMedGoogle Scholar
• GaBI Online. Biosimilars approved in Europe 2011 [cited 2019 Jul 19]. Available from: http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe
   Google Scholar
• Jurczak W, Moreira I, Kanakasetty GB, et al. Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study. Lancet Haematol. 2017 Aug;4(8):e350–e361. PubMed PMID: 28712941.
   PubMed Web of Science ®Google Scholar
• Jaeger U. Rituximab biosimilars open new horizons in immunotherapy. ESMO Open. 2017;2(3):e000234. PubMed PMID: 29209531; PubMed Central PMCID: PMC5703380
   PubMed Web of Science ®Google Scholar
• Cartron G, Watier H, Golay J, et al. From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004 Nov 01;104(9):2635–2642. PubMed PMID: 15226177.
   PubMed Web of Science ®Google Scholar
• Boross P, Leusen JH. Mechanisms of action of CD20 antibodies. Am J Cancer Res. 2012;2(6):676–690. PubMed PMID: 23226614; PubMed Central PMCID: PMC3512181.
   PubMed Web of Science ®Google Scholar
• Abulayha A, Bredan A, El Enshasy H, et al. Rituximab: modes of action, remaining dispute and future perspective. Future Oncol. 2014;10(15):2481–2492.
   PubMed Web of Science ®Google Scholar
• Tipton TR, Roghanian A, Oldham RJ, et al. Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies. Blood. 2015 Mar 19;125(12):1901–1909. PubMed PMID: 25631769.
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005 Feb 15;105(4):1417–1423. PubMed PMID: 15494430.
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008 Oct 01;26(28):4579–4586. PubMed PMID: 18662969.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005 Dec 01;106(12):3725–3732. PubMed PMID: 16123223.
   PubMed Web of Science ®Google Scholar
• Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007 May 20;25(15):1986–1992. PubMed PMID: 17420513.
   PubMed Web of Science ®Google Scholar
• Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood. 2008 Dec 15;112(13):4824–4831. PubMed PMID: 18799723.
   PubMed Web of Science ®Google Scholar
• Bachy E, Houot R, Morschhauser F, et al. Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. Haematologica. 2013 Jul;98(7):1107–1114. PubMed PMID: 23645690; PubMed Central PMCID: PMC3696615.
   PubMed Web of Science ®Google Scholar
• Federico M, Luminari S, Dondi A, et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol. 2013 Apr 20;31(12):1506–1513. PubMed PMID: 23530110.
   PubMed Web of Science ®Google Scholar
• Rummel M, Kaiser U, Balser C, et al. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016 Jan;17(1):57–66. PubMed PMID: 26655425.
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Weaver R, Alkuzweny B, et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol. 2004 Dec 1;22(23):4711–4716. PubMed PMID: 15483015.
   PubMed Web of Science ®Google Scholar
• van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006 Nov 15;108(10):3295–3301. PubMed PMID: 16873669.
   PubMed Web of Science ®Google Scholar
• Salles GA, Seymour JF, Feugier P, et al. Long term follow-up of the PRIMA study: half of patients receiving rituximab maintenance remain progression free at 10 years. Blood. 2017;130(Supplement 1):486.
   Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002 Jan 24;346(4):235–242. PubMed PMID: 11807147.
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005 Jun 20;23(18):4117–4126. PubMed PMID: 15867204.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010 Sep 23;116(12):2040–2045. PubMed PMID: 20548096; PubMed Central PMCID: PMC2951853.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006 Jul 01;24(19):3121–3127. PubMed PMID: 16754935.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006 May;7(5):379–391. PubMed PMID: 16648042.
   PubMed Web of Science ®Google Scholar
• Gaidzik VI, Bullinger L, Schlenk RF, et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol. 2011 Apr 1;29(10):1364–1372. PubMed PMID: 21343560.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010 Sep 20;28(27):4184–4190. PubMed PMID: 20660832; PubMed Central PMCID: PMC3664033.
   PubMed Web of Science ®Google Scholar
• Vellenga E, van Putten WL, van ‘t Veer MB, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood. 2008 Jan 15;111(2):537–543. PubMed PMID: 17971487.
   PubMed Web of Science ®Google Scholar
• Jermann M, Jost LM, Taverna C, et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol. 2004 Mar;15(3):511–516. PubMed PMID: 14998858.
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004 May 15;103(10):3684–3688. PubMed PMID: 14739217.
   PubMed Web of Science ®Google Scholar
• Mey UJ, Olivieri A, Orlopp KS, et al. DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis. Leuk Lymphoma. 2006 Dec;47(12):2558–2566. PubMed PMID: 17169800.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010 Oct 02;376(9747):1164–1174. PubMed PMID: 20888994.
   PubMed Web of Science ®Google Scholar
• Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010 Apr 01;28(10):1756–1765. PubMed PMID: 20194844.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas 2019 [cited 2019 Jul 19]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf
   Google Scholar
• European Medicines Agency (EMA). Guideline on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues 2012 [cited 2019 Jul 19]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-monoclonal-antibodies-non-clinical_en.pdf
   Google Scholar
• Food and Drug Administration. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product 2015. [cited 2019 Jul 19]. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm291128.pdf
   Google Scholar
• Kishioka Y, editor. Regulatory framework for biotherapeutic products including similar biotherapeutic products. 1st Malaysia-Japan Symposium on Pharmaceutical Regulatory System; 2015; Kuala Lumpur, Malaysia.
   Google Scholar
• Therapeutic Goods Administration. Biosimilar medicines regulation. Version 2.2, April 2018. [cited 2019 Jul 19]. Available from: https://www.tga.gov.au/publication/biosimilar-medicines-regulation
   Google Scholar
• Vulto AG, Jaquez OA. The process defines the product: what really matters in biosimilar design and production?. Rheumatology (Oxford). 2017 Aug 1;56(suppl_4):iv14–iv29. PubMed PMID: 28903544; PubMed Central PMCID: PMC5850795
   PubMed Web of Science ®Google Scholar
• Tsuruta LR, Lopes Dos Santos M, Moro AM. Biosimilars advancements: moving on to the future. Biotechnol Prog. 2015;31(5):1139–1149. PubMed PMID: 25708573
   PubMed Web of Science ®Google Scholar
• Berkowitz SA, Engen JR, Mazzeo JR, et al. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov. 2012 Jun 29;11(7):527–540. PubMed PMID: 22743980; PubMed Central PMCID: PMC3714370.
   PubMed Web of Science ®Google Scholar
• Bui LA, Hurst S, Finch GL, et al. Key considerations in the preclinical development of biosimilars. Drug Discov Today. 2015 May;20(Suppl 1):3–15. PubMed PMID: 25912284.
   PubMed Web of Science ®Google Scholar
• Al-Sabbagh A, Olech E, McClellan JE, et al. Development of biosimilars. Semin Arthritis Rheum. 2016 Apr;45(5 Suppl):S11–8. PubMed PMID: 26947440.
   PubMed Web of Science ®Google Scholar
• Alten R, Cronstein BN. Clinical trial development for biosimilars. Semin Arthritis Rheum. 2015 Jun;44(6 Suppl):S2–8. PubMed PMID: 26058550.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues 2014. [cited 2019 Jul 19]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf
   Google Scholar
• Rugo HS, Linton KM, Cervi P, et al. A clinician’s guide to biosimilars in oncology. Cancer Treat Rev. 2016 May;46:73–79. PubMed PMID: 27135548.
   PubMed Web of Science ®Google Scholar
• Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol. 2003 Apr 1;21(7):1404–1411. PubMed PMID: 12663734
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration (FDA). Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics 2018 [cited 2019 Jul 19]. Available from: https://www.fda.gov/downloads/Drugs/Guidances/ucm071590.pdf
   Google Scholar
• US Food and Drug Administration (FDA). Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry 2015 [cited 2019 Jul 19]. Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf
   Google Scholar
• US Food and Drug Administration (FDA). Considerations in demonstrating interchangeability with a reference product guidance for industry. DRAFT GUIDANCE 2017 [cited 2019 Jul 19]. Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM537135.pdf
   Google Scholar
• Fleming TR, Rothmann MD, Lu HL. Issues in using progression-free survival when evaluating oncology products. J Clin Oncol. 2009 Jun 10;27(17):2874–2880. PubMed PMID: 19414672; PubMed Central PMCID: PMC2698020
   PubMed Web of Science ®Google Scholar
• Saad ED, Katz A, Hoff PM, et al. Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol. 2010 Jan;21(1):7–12. PubMed PMID: 19901012.
   PubMed Web of Science ®Google Scholar
• Shi Q, Flowers CR, Hiddemann W, et al. Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: an individual patient-level analysis of multiple randomized trials. J Clin Oncol. 2017 Feb 10;35(5):552–560. PubMed PMID: 28029309.
   PubMed Web of Science ®Google Scholar
• Visser J, Feuerstein I, Stangler T, et al. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. BioDrugs. 2013 Oct;27(5):495–507. PubMed PMID: 23649935; PubMed Central PMCID: PMC3775154.
   PubMed Web of Science ®Google Scholar
• Da Silva A, Kronthaler U, Koppenburg V, et al. Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013. Leuk Lymphoma. 2014 Jul;55(7):1609–1617. PubMed PMID: 24024472; PubMed Central PMCID: PMC4133973.
   PubMed Web of Science ®Google Scholar
• Yoo DH, Suh CH, Shim SC, et al. A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2017 Mar;76(3):566–570. PubMed PMID: 27624791; PubMed Central PMCID: PMC5446025.
   PubMed Web of Science ®Google Scholar
• Yoo DH, Suh CH, Shim SC, et al. Efficacy, safety and pharmacokinetics of up to two courses of the rituximab biosimilar CT-P10 versus innovator rituximab in patients with rheumatoid arthritis: results up to week 72 of a Phase I randomized controlled trial. BioDrugs. 2017 Aug;31(4):357–367. PubMed PMID: 28612179; PubMed Central PMCID: PMC5548818.
   PubMed Web of Science ®Google Scholar
• Park W, Suh CH, Shim SC, et al. Efficacy and safety of switching from innovator rituximab to biosimilar CT-P10 compared with continued treatment with CT-P10: results of a 56-week open-label study in patients with rheumatoid arthritis. BioDrugs. 2017 Aug;31(4):369–377. PubMed PMID: 28600696; PubMed Central PMCID: PMC5548826.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. NCT01534949: provide initial evidence of safety, pharmacokinetics, pharmacodynamics, and efficacy to support the pivotal CT-P10 therapeutic equivalence trial (Triad-DLBCL) 2012 [cited 2019 Jul 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT01534949
   Google Scholar
• Park W, Bozic-Majstorovic L, Milakovic D, et al. Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial. mAbs. 2018;10(6):934–943. PubMed PMID: 30010481; PubMed Central PMCID: PMC6152436.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Cohen SB, Tony HP, et al. A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis. 2017 Sep;76(9):1598–1602. PubMed PMID: 28637670; PubMed Central PMCID: PMC5561377.
   PubMed Web of Science ®Google Scholar
• Ogura M, Sancho JM, Cho SG, et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial. Lancet Haematol. 2018 Nov;5(11):e543–e553. PubMed PMID: 30389036.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. NCT01933516: GP2013 in Japanese patients with CD20 positive low tumor burden indolent b-cell non-Hodgkin’s lymphoma 2013 [cited 2019 Jul 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT01933516
   Google Scholar
• Kim WS, Buske C, Ogura M, et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. Lancet Haematol. 2017;4(8):e362–e373.
   PubMed Web of Science ®Google Scholar
• Tony HP, Kruger K, Cohen SB, et al. Brief report: safety and immunogenicity of rituximab biosimilar GP2013 after switch from reference rituximab in patients with active rheumatoid arthritis. Arthritis Care Res (Hoboken). 2019 Jan;71(1):88–94. PubMed PMID: 30295429.
   PubMed Web of Science ®Google Scholar
• GaBI Online. Rituximab biosimilar submitted to EMA and Rituxan gains extra indication 2018. [cited 2019 Jul 19]. Available from: http://www.gabionline.net/Biosimilars/News/Rituximab-biosimilar-submitted-to-EMA-and-Rituxan-gains-extra-indication
   Google Scholar
• Ryan AM, Sokolowski SA, Ng CK, et al. Comparative nonclinical assessments of the proposed biosimilar PF-05280586 and rituximab (MabThera(R)). Toxicol Pathol. 2014 Oct;42(7):1069–1081. PubMed PMID: 24604381.
   PubMed Web of Science ®Google Scholar
• Cohen S, Emery P, Greenwald M, et al. A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis. Br J Clin Pharmacol. 2016 Jul;82(1):129–138. PubMed PMID: 26909489; PubMed Central PMCID: PMC4917800.
   PubMed Web of Science ®Google Scholar
• Williams JH, Hutmacher MM, Zierhut ML, et al. Comparative assessment of clinical response in patients with rheumatoid arthritis between PF-05280586, a proposed rituximab biosimilar, and rituximab. Br J Clin Pharmacol. 2016 Dec;82(6):1568–1579. PubMed PMID: 27530379; PubMed Central PMCID: PMC5099556.
   PubMed Web of Science ®Google Scholar
• Cohen SB, Burgos-Vargas R, Emery P, et al. Extension study of PF-05280586, a potential rituximab biosimilar, versus rituximab in subjects with active rheumatoid arthritis. Arthritis Care Res (Hoboken). 2018 Nov;70(11):1598–1606. PubMed PMID: 29692005; PubMed Central PMCID: PMC6221032.
   PubMed Web of Science ®Google Scholar
• Sharman J, Liberati AM, Silva RS, et al. A randomized, double-blind efficacy and safety study of PF-05280586 (a potential rituximab biosimilar) compared with rituximab reference product (MabThera®) in subjects with previously untreated CD20-positive, low tumor burden follicular lymphoma (LTB-FL). 60th American Society of Hematology Annual Meeting; 02 December 2018; San Diego, CA, USA.
   Google Scholar
• Seigelchifer M, Corley E, Fresnillo G, et al. Development of RTXM83 (a potential rituximab biosimilar): in vitro and in vivo comparability with MabThera. J Clin Oncol. 2014;32(15_suppl):e14020.
   Google Scholar
• Cuello HA, Segatori VI, Alberto M, et al. Comparability of antibody-mediated cell killing activity between a proposed biosimilar RTXM83 and the originator rituximab. BioDrugs. 2016 Jun;30(3):225–231. PubMed PMID: 27053342.
   PubMed Web of Science ®Google Scholar
• Candelaria M, González DE, Delamain MT, et al. Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study. Leuk Lymphoma. 2019 Jul 4:1-11. doi: 10.1080/10428194.2019.1633632. PubMed PMID: 31272251.
   Google Scholar
• McBride H, Maher G, Sweet H, et al. Demonstration of functional similarity of proposed biosimilar ABP 798 to rituximab. 22nd Congress of European Hematology Association; 22-25 June 2017; Madrid, Spain.
   Google Scholar
• ClinicalTrials.gov. NCT02747043. Study to assess if ABP798 is safe & effective in treating non Hodgkin lymphoma compared to rituximab (JASMINE) 2016 [cited 2019 Jul 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT02747043
   Google Scholar
• ClinicalTrials.gov. NCT02792699. Study to assess if ABP798 is safe & effective in treating moderate to severe rheumatoid arthritis compared to rituximab 2016 [cited 2019 Jul 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT02792699
   Google Scholar
• ClinicalTrials.gov. NCT02617485. MabionCD20® compared to MabThera® in lymphoma patients 2015 [cited 2019 Jul 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT02617485
   Google Scholar
• ClinicalTrials.gov. NCT02468791. MabionCD20® compared to MabThera® in patients with rheumatoid arthritis 2015 [cited 2019 Jul 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT02468791
   Google Scholar
• ClinicalTrials.gov. NCT02809053. A randomized, double-blind, multi-center, multi-national trial to evaluate the efficacy, safety, and immunogenicity of SAIT101 versus rituximab as a first-line immunotherapy treatment in patients with low tumor burden follicular lymphoma (RAMO-2) 2016 [cited 2019 Jul 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT02809053
   Google Scholar
• IQVIA Institute for Human Data Science. Global oncology trends 2019: therapeutics, clinical development and health system implications 2019 [cited 2019 Jul 19]. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/global-oncology-trends-2019.pdf
   Google Scholar
• Cherny N, Sullivan R, Torode J, et al. ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe. Ann Oncol. 2016 Aug;27(8):1423–1443. PubMed PMID: 27457309.
   PubMed Web of Science ®Google Scholar
• Vulto A, van Harten W, Simoens S, et al. Can we continue to afford access to cancer treatment? Eur Oncol Haematol. 2017;13(02):114.
   Google Scholar
• Gotham D, Barber MJ, Hill A. Production costs and potential prices for biosimilars of human insulin and insulin analogues. BMJ Glob Health. 2018;3(5):e000850. PubMed PMID: 30271626; PubMed Central PMCID: PMC6157569.
   PubMed Web of Science ®Google Scholar
• Migliavacca Zucchetti B, Nicolo E, Curigliano G. Biosimilars for breast cancer. Expert Opin Biol Ther. 2019 Jul 10:1–7. PubMed PMID: 31248290.
   PubMed Web of Science ®Google Scholar
• Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q. 2018 Mar;7(4):3. PubMed PMID: 30083415; PubMed Central PMCID: PMC6075809.
   PubMedGoogle Scholar
• Giuliani J, Bonetti A. The economic impact of biosimilars in oncology and hematology: the case of trastuzumab and rituximab. Anticancer Res. 2019 Jul;39(7):3971–3973. PubMed PMID: 31262930
   PubMed Web of Science ®Google Scholar
• Manova M, Savova A, Vasileva M, et al. Comparative price analysis of biological products for treatment of rheumatoid arthritis. Front Pharmacol. 2018;9:1070. PubMed PMID: 30294275; PubMed Central PMCID: PMC6158404.
   PubMed Web of Science ®Google Scholar
• Lopes G, Vulto A, Wilking N, et al. Potential solutions for sustaining the costs of cancer drugs. Eur Oncol Haematol. 2017;13(02):102.
   Google Scholar
• Bauchner H, Fontanarosa PB, Golub RM. Scientific evidence and financial obligations to ensure access to biosimilars for cancer treatment. JAMA. 2017 Jan 3;317(1):33–34. PubMed PMID: 27918795.
   PubMed Web of Science ®Google Scholar
• Schellekens H, Smolen JS, Dicato M, et al. Safety and efficacy of biosimilars in oncology. Lancet Oncol. 2016 Nov;17(11):e502–e509. PubMed PMID: 27819248.
   PubMed Web of Science ®Google Scholar
• Quintiles IMS. The impact of biosimilar competition in Europe 2017. [cited 2019 Jul 19]. Available from: https://www.medicinesforeurope.com/wp-content/uploads/2017/05/IMS-Biosimilar-2017_V9.pdf
   Google Scholar
• Cornes P. The economic pressures for biosimilar drug use in cancer medicine. Target Oncol. 2012 Mar;7(Suppl 1):S57–67. PubMed PMID: 22249658; PubMed Central PMCID: PMC3291824.
   PubMed Web of Science ®Google Scholar
• Kay J. Biosimilars: new or Deja Vu? Arthritis Rheumatol. 2016;68(5):1049–1052.
   PubMed Web of Science ®Google Scholar
• Dorner T, Kay J. Biosimilars in rheumatology: current perspectives and lessons learnt. Nat Rev Rheumatol. 2015 Dec;11(12):713–724. PubMed PMID: 26282080.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Perrault R, Zhao Y, et al. SpeB proteolysis with imaged capillary isoelectric focusing for the characterization of domain-specific charge heterogeneities of reference and biosimilar rituximab. J Chromatogr B. 2016;1020:148–157.
   PubMed Web of Science ®Google Scholar
• Nupur N, Chhabra N, Dash R, et al. Assessment of structural and functional similarity of biosimilar products: rituximab as a case study. mAbs. 2018 Jan;10(1):143–158. PubMed PMID: 29200314; PubMed Central PMCID: PMC5800382.
   PubMed Web of Science ®Google Scholar
• Flores-Ortiz LF, Campos-Garcia VR, Pardomo-Abunez FC, et al. Physicochemical properties of rituximab. J Liquid Chromatogr Related Technol. 2014;37(10):1438–1452.
   Web of Science ®Google Scholar
• Gota V, Karanam A, Rath S, et al. Population pharmacokinetics of Reditux, a biosimilar rituximab, in diffuse large B-cell lymphoma. Cancer Chemother Pharmacol. 2016 Aug;78(2):353–359. PubMed PMID: 27329361.
   PubMed Web of Science ®Google Scholar
• Hegde A, Vasdev V, Shanamuganandan K, et al. Safety and efficacy of an anti-CD20 monoclonal antibody (RedituxTM) in Indian patients with seropositive rheumatoid arthritis. Indian J Rheumatol. 2018;13:20–25.
   Web of Science ®Google Scholar
• Roshique KK, Ravindran V. Efficacy and safety of a biosimilar rituximab in biologic naive patients with active rheumatoid arthritis. Clin Rheumatol. 2015 Jul;34(7):1289–1292. PubMed PMID: 26032432.
   PubMed Web of Science ®Google Scholar
• Roy PS, John S, Karankal S, et al. Comparison of the efficacy and safety of rituximab (Mabthera) and its biosimilar (Reditux) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: A retrospective analysis. Indian J Med Paediatr Oncol. 2013 Oct;34(4):292–298. PubMed PMID: 24604960; PubMed Central PMCID: PMC3932598.
   PubMedGoogle Scholar
• Ganesan P, Sagar TG, Kannan K, et al. Long-term outcome of diffuse large B-cell lymphoma: impact of biosimilar rituximab and radiation. Indian J Cancer. 2017;54:430–435.
   PubMed Web of Science ®Google Scholar
• Prakash G, Malhotra P, Khadawal A, et al. Infusion related hypersensitivity reactions with biosimilar anti CD-20 monoclonal antibody rituximab in Indian patients: a retrospective study. Indian J Hematol Blood Transfusion. 2018;34(2):273–277.
   PubMed Web of Science ®Google Scholar
• Bhati M, Bandyopadhyay S. Efficacy and safety of an anti-CD20 monoclonal antibody (Reditux) for the treatment of patients with moderate to severe rheumatoid arthritis following the failure of conventional synthetic disease-modifying anti-rheumatic drugs. Clin Rheumatol. 2016 Aug;35(8):1931–1935. PubMed PMID: 27334114
   PubMed Web of Science ®Google Scholar
• Kaplanov K, Zaritskiy A, Alexeev S, et al. Key results of international randomized open-label clinical study of BCD-020 (rituximab biosimilar candidate) in patients with B-cell non-Hodgkin’s lymphoma. Blood. 2014;124:5467.
   Web of Science ®Google Scholar
• Eremeeva A, Chernyaeva E, Ibvanov R, et al. Comparison of efficacy and safety of rituximab biosimilar, BCD-020, and innovator rituximab in patients with active rheumatoid arthritis refractory to TNFA inhibitors. Ann Rheum Dis. 2016;75(Suppl 2):FRI0224.
   Web of Science ®Google Scholar
• Baer WH II, Maini A, Jacobs I. Barriers to the access and use of rituximab in patients with non-Hodgkin’s lymphoma and chronic lymphocytic leukemia: a physician survey. Pharmaceuticals (Basel). 2014 May 07;7(5):530–544. PubMed PMID: 24810947; PubMed Central PMCID: PMC4035768
   PubMedGoogle Scholar
• World Health Organization (WHO). Economic crisis, health systems and health in Europe: country experience 2015 [cited 2019 Jul 19]. Available from: http://www.euro.who.int/__data/assets/pdf_file/0010/279820/Web-economic-crisis-health-systems-and-health-web.pdf?ua=1
   Google Scholar
• IQVIA Institute for Human Data Science. Advancing biosimilar sustainability in Europe: a multi-stakeholder assessment 2018 [cited 2019 Jul 19]. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/advancing-biosimilar-sustainability-in-europe.pdf
   Google Scholar
• Tinsley SM, Grande C, Olson K, et al. Potential of biosimilars to increase access to biologics: considerations for advanced practice providers in oncology. J Adv Pract Oncol. 2018;9(7):699–716. PubMed PMID: 31249718; PubMed Central PMCID: PMC6570521.
   PubMedGoogle Scholar